Brooks Laboratories

Brooks Laboratories EBITDA per Employee

The EBITDA per Employee of Brooks Laboratories (BROOKS.NS) as of Oct 21, 2026 is 184,790.54 INR. In the previous year, EBITDA per Employee was 166,854.73 INR — a change of 10.75% (higher).

EBITDA per Employee

184,790.54INR

YoY

10.75%

Last updated:

EBITDA per Employee of Brooks Laboratories is 2026 184,790.54 INR. EBITDA per Employee of Brooks Laboratories was 2025 166,854.73 INR. It decreases by 10.75% higher compared to the previous year.

The Brooks Laboratories EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-185,314.19 INR
Jan 1, 2020
-78,179.05 INR
Jan 1, 2021
42,064.19 INR
Jan 1, 2022
509,726.35 INR
Jan 1, 2023
4,334.46 INR
Jan 1, 2024
100,408.78 INR
Jan 1, 2025
166,854.73 INR
Jan 1, 2026
184,790.54 INR
The Brooks Laboratories EBITDA per Employee history
YEAREBITDA per EmployeeYoY
184,790.54INR+10.75%
166,854.73INR+66.18%
100,408.78INR+2,216.52%
4,334.46INR-99.15%
509,726.35INR+1,111.78%
42,064.19INR-153.80%
-78,179.05INR-57.81%
-185,314.19INR-36.80%
-293,239.86INR-233.15%
220,233.11INR-45.58%
404,692.57INR+4.62%
386,837.84INR+36.29%
283,830.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd. manufactures pharmaceutical products including Carbapenem category drugs such as Imipenem 250mg + Cilastatin 250mg, Meropenem 125mg, and Doripenem 500mg. The company produces Penicillins in injections, tablets, and dry syrup forms, along with General category products like liquid injections, dry powder injections, and eye/ear drops. Brooks Laboratories markets its pharmaceuticals nationally and internationally to regulated markets through its manufacturing plants in Baddi, Himachal Pradesh. The firm generates revenue by selling these dosage forms to healthcare providers and distributors in regulated pharmaceutical markets. The company's product portfolio includes specific formulations like Iron sucrose 100mg/5ml liquid injections under the General category. Brooks Laboratories targets regulated markets globally for its Carbapenem, Penicillin, and General category products. Its manufacturing operations at Baddi enable nationwide and international distribution of pharmaceuticals. Revenue is derived from the sale of these branded and generic pharmaceutical products to hospitals, pharmacies, and international buyers in compliant markets. Brooks Laboratories focuses on producing injectable and oral dosage forms including tablets, dry syrup, and eye/ear drops. The company's Carbapenem category features Meropenem 1000mg+Tazobactam 500mg and Doripenem 1000mg. Penicillins are available as injections, tablets, and dry syrup. The firm's revenue model relies on direct sales of these pharmaceutical products to healthcare institutions and distributors in regulated markets, ensuring compliance with international pharmaceutical standards. Brooks Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brooks Laboratories stock

EBITDA per Employee of Brooks Laboratories is 184,790.54 INR in 2026.

EBITDA per Employee of Brooks Laboratories changed from 166,854.73 INR to 184,790.54 INR, representing a 10.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Brooks Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Brooks Laboratories

All Key Metrics — Brooks Laboratories